Association Between Mycophenolate Mofetil Use and Subsequent Infections Among Hospitalized Patients with Systemic Lupus Erythematosus: A Nested Case –Control Study
ConclusionsMMF use is associated with various type of infections in patients with SLE, particularly in those with longer use, older age, complications with comorbidities, and concomitant use of CYC or other immunosuppressants. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 24, 2023 Category: Rheumatology Source Type: research
A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
ConclusionsIn this real-world cohort of patients with RA, treatment with upadacitinib was associated with early and significant improvement in RAPID3, pain, morning stiffness, and fatigue regardless of prior TNFi experience. Clinically meaningful improvement in RAPID3 patient-reported disease activity was observed as early as week 1, with continued improvement reported through week 12. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 20, 2023 Category: Rheumatology Source Type: research
Correction: Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 20, 2023 Category: Rheumatology Source Type: research
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
ConclusionBaricitinib demonstrated effectiveness in the real-world setting with a consistent safety profile observed in clinical studies. Better persistence rates for baricitinib compared to bDMARDs with improvement in PROs were reported, although baricitinib-treated patients had RA with poor prognostic characteristics. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 16, 2023 Category: Rheumatology Source Type: research
Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
ConclusionsIn each treatment group, MDA domains less frequently achieved were PtGA and pain, suggesting that “patient-driven domains” are still an unmet need.Due to the study design and the low number of patients in some groups, it is not possible to clearly define which MDA domain was achieved or not based on treatment; however, it seems that some differences could be present. If larger and prospective studies confirm our preliminary results, we could move toward a personalized/domain treatment approach in PsA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 16, 2023 Category: Rheumatology Source Type: research
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
ConclusionThe data from this study confirm the findings of previous randomized controlled trials suggesting UPA is an effective treatment for active PsA without any new safety signals in patients from daily clinical practice.Clinical Trial RegistrationClinicalTrials.gov identifier, NCT04758117. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 11, 2023 Category: Rheumatology Source Type: research
Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
AbstractFilgotinib is an oral preferential Janus kinase 1 inhibitor that demonstrated significant reductions in radiographic progression, with an acceptable tolerability and safety profile, vs placebo in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX-IR; FINCH 1) and vs MTX in MTX-naïve patients with RA (FINCH 3). International treatment guidelines identify multiple poor prognostic factors (PPFs) associated with worse disease outcomes among patients with RA. However, questions remain both about the clinical utility of considering PPFs and about which PPFs should drive treatmen...
Source: Rheumatology and Therapy - September 5, 2023 Category: Rheumatology Source Type: research
Correction: Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 5, 2023 Category: Rheumatology Source Type: research
Is the Rate of Responders to Hyaluronic Acid Injection for Patients with Knee Osteoarthritis Stable Over Time? Post hoc Analyses of a 6-Month Follow-Up Study
ConclusionsAn early response of a single injection of sodium hyaluronate plus sorbitol is predictive of long-term response, up to 24 weeks. Patients with a poorer physical function may best benefit from the treatment. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 30, 2023 Category: Rheumatology Source Type: research
Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert ’s Document Based on a Systematic Literature Review and Extended Delphi Process
ConclusionsThese recommendations are intended to complement guidelines by helping health professionals address and manage specific groups of patients, particular clinical scenarios, and gaps in axSpA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 30, 2023 Category: Rheumatology Source Type: research
Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
ConclusionsPsA patients treated with IXE in a real-world setting show high treatment persistence through 104 weeks and improvements in disease activity after treatment initiation. This suggests that IXE could be an effective treatment for patients with PsA.Retrospectively registeredDate of registration: 25th May 2021. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 30, 2023 Category: Rheumatology Source Type: research
Real-World Immunosuppressant Treatment Patterns for Patients with Lupus Nephritis in the United States
ConclusionsAround a quarter of patients with LN initiating immunosuppressant therapy switched within 12 months, while a fifth re-initiated induction therapy within 12 months. Use of high corticosteroid doses were observed during 24 months of follow-up. These data suggest that many patients do not respond to existing standard LN therapies. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 30, 2023 Category: Rheumatology Source Type: research
Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study
ConclusionsReal-world data are a key component of the evidence supporting the effectiveness of drugs and are of interest to all stakeholders. Our comparative study demonstrated the effectiveness of MMF in LN induction therapy was at least equivalent to intravenous CYC, with superior tolerance. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 30, 2023 Category: Rheumatology Source Type: research
The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study
ConclusionsAlthough the benefit –risk profile for febuxostat is considered favorable for the treatment of hyperuricemia in certain patients with gout, real-world febuxostat utilization decreased during the study period, presumably in response to the label change. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 30, 2023 Category: Rheumatology Source Type: research
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
ConclusionsFilgotinib reduced peripheral protein biomarkers associated with JAK/STAT signaling, inflammatory signaling, immune cell migration, and bone resorption as soon as W4 in FINCH 1. Effects were dose-dependent and consistent with the clinical efficacy of filgotinib observed in FINCH 1. The changes in peripheral biomarkers associated with filgotinib treatment in methotrexate-experienced patients are consistent with changes observed in both methotrexate-na ïve and biologic disease-modifying antirheumatic drug-experienced RA populations. These data demonstrate dose-dependent effects of preferential JAK1 inhibition by ...
Source: Rheumatology and Therapy - August 30, 2023 Category: Rheumatology Source Type: research
